# Nikolaus Marx

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nikolaus-marx/

## Facts

| Field | Value |
| --- | --- |
| Citations | 54,393 |
| Field | Diabetes Treatment and Management |
| h-index | 88 |
| i10-index | 403 |
| Last Known Institution | Novo Nordisk (Denmark) |
| OpenAlex ID | https://openalex.org/A5019976194 |
| ORCID iD | https://orcid.org/0000-0001-6141-634X |
| Works | 991 |

## Researcher papers

Showing 12 of 13.

- [2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD](https://scholariq.org/papers/2019-esc-guidelines-on-diabetes-pre-diabetes-and-cardiovascular-diseases/)
- [Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://scholariq.org/papers/empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction/)
- [2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)](https://scholariq.org/papers/2024-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in/)
- [Cardiovascular Disease in Chronic Kidney Disease](https://scholariq.org/papers/cardiovascular-disease-in-chronic-kidney-disease/)
- [2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes](https://scholariq.org/papers/2023-esc-guidelines-for-the-management-of-cardiovascular-disease-in-patients/)
- [Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk](https://scholariq.org/papers/effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with/)
- [Swarm Learning for decentralized and confidential clinical machine learning](https://scholariq.org/papers/swarm-learning-for-decentralized-and-confidential-clinical-machine-learning/)
- [Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes](https://scholariq.org/papers/effect-of-linagliptin-vs-glimepiride-on-major-adverse-cardiovascular-outcomes-in/)
- [The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia](https://scholariq.org/papers/the-residual-risk-reduction-initiative-a-call-to-action-to-reduce-residual/)
- [Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status](https://scholariq.org/papers/effect-of-empagliflozin-on-cardiovascular-and-renal-outcomes-in-patients-with/)
- [Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-high-risk-type-2-diabetes/)
- [Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials](https://scholariq.org/papers/benefits-and-harms-of-drug-treatment-for-type-2-diabetes-systematic-review-and/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)

## Researcher university

- [Novo Nordisk (Denmark)](https://scholariq.org/institutions/novo-nordisk-denmark/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.